Anemia Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Anemia Treatment Market Trends and Insights

Escalating Worldwide Incidence and Earlier Diagnosis of Anemia

The combined effects of demographic change, improved screening, and AI-supported imaging uncover previously hidden cases across populations. . The World Health Organization reports that 29.9% of women aged 15-49 and 39.8% of children aged 6-59 months suffered from anemia globally, with the African region showing the highest prevalence at 60.2% among children under five.^{[1]Source: World Health Organization, “Global Health Observatory – Anaemia in Women and Children,” who.int} Smartphone-based tests that deliver hemoglobin values in under one minute widen access and help providers intervene sooner, increasing patient volumes in the anemia treatment market.

Growing Prevalence of Comorbid Chronic Diseases

Chronic kidney disease, cancer, and inflammatory disorders each elevate anemia risk and require more complex interventions than iron replacement alone. The 2025 KDIGO guideline recognizes the need to combine ESAs and emerging HIF-PH inhibitors to manage renal anemia safely. As oncology treatment volumes rise, supportive anemia care preserves quality of life for up to 70% of patients receiving chemotherapy, supporting steady demand in the anemia treatment market.

Regulatory Approvals and Pipeline Progress for Novel Therapeutic Classes

Gene editing and oral HIF-PH inhibitors signal a structural shift in treatment standards. FDA clearance of CASGEVY, the first CRISPR-based therapy for sickle cell disease, sets a precedent for curative approaches despite a per-patient cost above USD 3 million. Daprodustat and vadadustat confirmations validate oral modulation of hypoxia-inducible pathways, challenging ESA dominance while reinforcing innovation-led growth for the anemia treatment market.

Government Nutrition Programs for Women of Reproductive Age

Large-scale iron and folic acid supplementation under India’s Anemia Mukt Bharat reaches six priority groups and includes digital testing tools, locking in predictable procurement volumes.^{[2]Source: Ministry of Health and Family Welfare India, “Anemia Mukt Bharat,” nhm.gov.in} Similar initiatives across Southeast Asia and parts of Africa underpin baseline demand for standard iron products, buffering market cycles tied to high-cost biologics.

ESA & Gene-Therapy Cost-Containment Pressures

Payers now require step-therapy, forcing oral iron trials ahead of intravenous options, while biosimilar ESAs chip away at branded pricing. Curative gene therapies face reimbursement hurdles given their high upfront cost, limiting access even where clinical value is clear. Payer policies increasingly emphasize step therapy requirements, mandating oral iron trials before approving expensive intravenous formulations, thereby delaying optimal treatment initiation. The emergence of biosimilar ESAs further pressures originator pricing while HIF-PH inhibitors face uncertainty regarding long-term cardiovascular safety profiles.

Safety Concerns (Thrombo-embolism, Iron Overload) Curb Use

Higher hemoglobin targets with ESAs raise stroke risk and trigger tighter dosing rules. Chronic transfusion accelerates iron overload, and chelation itself can cause liver injury, prompting clinicians to balance efficacy with organ protection. Patient adherence suffers as gastrointestinal side effects from oral iron formulations affect up to 45% of users, with severity correlating with age and BMI, necessitating personalized management strategies that increase healthcare resource utilization.^{[3]Source: Nutrients, “Impact of Side Effects on Anemia Therapy Compliance,” mdpi.com}

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Type: Iron Deficiency Drives Volume While Sickle Cell Accelerates Innovation

Iron deficiency anemia accounted for 44.68% of the anemia treatment market size in 2025, underlining its status as the widest clinical segment. High prevalence among women of child-bearing age and children ensures large-scale demand for low-cost iron therapy and supports volume-driven growth across both developed and emerging economies. Government procurement under mass supplementation schemes keeps standard iron products in steady circulation, maintaining leadership despite lower per-unit pricing.

Sickle cell anemia is projected to advance at an 8.15% CAGR, outpacing every other disease subtype within the anemia treatment market. Breakthrough therapies such as CASGEVY and related gene-editing candidates create premium subsegments that attract specialized funding and center-of-excellence models. Growing newborn screening in the United States and selected African countries further enlarges the addressable patient pool and accelerates diagnosis, steering attention toward curative rather than palliative care. The anemia treatment industry therefore sees value migration from high-volume, low-margin iron deficiency products to low-volume, high-margin gene therapies for hemoglobinopathies.

By Therapy Class: Intravenous Iron Leadership Challenged by HIF-PH Innovation

Intravenous iron captured 36.23% of revenue in 2025, supported by hospital protocols that favor rapid hemoglobin correction for severe cases. Products such as ferric carboxymaltose deliver single-dose convenience and reduce admission times, sustaining entrenched usage patterns among clinicians. This class continues to anchor the anemia treatment market, particularly in surgical and obstetric settings where immediate correction prevents transfusion.

HIF-PH inhibitors, forecast to grow at 7.90% through 2031, aim to close efficacy gaps in chronic kidney disease by stimulating endogenous erythropoietin under physiological limits. Oral delivery removes injection burdens, giving patients more autonomy and simplifying logistics in dialysis centers. Continued positive cardiovascular safety data could push these agents toward first-line status, gradually trimming dependence on ESAs. The anemia treatment industry thus balances a reliable intravenous iron base with an innovation pipeline that redefines long-term management.

By Route of Administration: Injectable Dominance Faces Oral Innovation Challenge

Injectables held 61.12% of 2025 revenue owing to entrenched use of ESAs, IV iron, and gene-based infusions. Hospital routines, cold-chain reliability in developed markets, and clinician familiarity secure ongoing preference for parenteral delivery. These factors safeguard current volume in the anemia treatment market even as payer pressure mounts.

Oral routes, advancing at 7.35% CAGR, receive momentum from tolerability-focused reformulations such as ACCRUFeR, which mitigates gastrointestinal distress for more than 50% of traditional ferrous-salt users. HIF-PH inhibitors exclusively rely on oral dosing, making convenience a key competitive lever. As consumer preference shifts toward home-based care, oral products are positioned to win incremental share, giving the anemia treatment market a dual-track structure of hospital-centric injectables and community-based oral regimens.

Geography Analysis

North America generated 37.05% of total sales in 2025, reflecting early adoption of premium therapies and insurance frameworks that reimburse high-cost gene editing, ESA biologics, and injectable irons. Comprehensive newborn screening and precision-medicine programs bolster uptake across rare anemia segments. Payer scrutiny, however, caps ESA growth and encourages biosimilar use, shaping a value-oriented procurement environment that still rewards innovation when strong clinical outcomes are demonstrated.

Europe presents steady but more price-sensitive expansion. Harmonized regulatory reviews permit rapid biosimilar penetration, spreading access to established biologics while containing costs. Countries such as Germany and the United Kingdom have adopted pathway funding for CRISPR therapies, yet negotiate outcomes-based contracts to align high upfront payments with long-term clinical benefit. Iron chelation combinations receive acceptance after favorable safety and efficacy evidence, reinforcing diversified therapy mixes across national health services.

Asia Pacific is the fastest-growing region at 8.02% CAGR through 2031, driven by widening insurance coverage, rising chronic disease loads, and government-led nutrition drives. China’s regulatory reforms speed approval of HIF-PH inhibitors, while domestic manufacturers scale generic IV iron, lowering average selling prices and boosting penetration. Smartphone-enabled diagnostics further lift test volumes, feeding prescription demand throughout the anemia treatment market.

Regulatory Landscape

Regulation of anemia therapeutics covers traditional drugs (oral and IV iron, ESAs) and newer modalities (HIF-PH inhibitors and gene-based therapies), with tighter attention on product safety, traceability, and access controls for higher-cost treatments. In the United States, FDA actions continue to add labeled treatment options while using tools such as Risk Evaluation and Mitigation Strategy (REMS) where needed, as illustrated by the January 2026 FDA approval of mitapivat for anemia in adults with alpha- or beta-thalassemia under a REMS. Separately, supply-chain compliance is tightened through the Drug Supply Chain Security Act (DSCSA), which requires interoperable electronic product tracing at the package level (21 USC 360eee-1), affecting manufacturers and distributors of injectable biologics and IV iron products.

In Europe, EMA and European Commission decisions shape therapy availability and pharmacovigilance expectations across anemia indications. EMA granted marketing authorization for Rytelo in March 2025 for transfusion-dependent anemia in adults with low- to intermediate-1 risk myelodysplastic syndromes, and EMA issued an October 2024 direct healthcare professional communication linked to suspension of the EU marketing authorization for Oxbryta in sickle cell disease, reinforcing safety-led regulatory oversight. Separately, the European Union is advancing a framework to strengthen security of supply for critical medicinal products, which is expected to influence procurement and localization considerations for anemia medicines alongside ongoing pharmacovigilance requirements.

Market Opportunities and Future Outlook

Guideline updates and regulatory momentum are creating actionable whitespace in chronic kidney disease (CKD) anemia, thalassemia, and selected rare anemia subtypes, especially where oral options reduce administration burden and where dosing frequency can be extended. KDIGO released its updated 2026 Clinical Practice Guideline for the Management of Anemia in CKD (April 2026), incorporating newer evidence on HIF-PH inhibitors and iron management, and revising iron-deficiency nomenclature. This steers demand toward products that fit standardized treatment algorithms, and toward real-world evidence packages that address payer and safety scrutiny. On the product side, regulatory actions broaden addressable segments, including the European Medicines Agency confirmation of adoption of a positive opinion in March 2026 to extend ferric maltol (FeRACCRU) to pediatric patients aged 12 years and older, opening a defined adolescent population for oral iron therapy.

Localization and supply partnerships are also supporting reach for established injectables, while innovation efforts target specialized anemia populations with premium pricing and trial activity. In April 2026, China Medical System Holdings signed a 15-year exclusive commercialization and supply agreement with Pharmacosmos A/S for Monofer and Cosmofer in China, pointing to a direct route for multinational-to-regional partnering around IV iron access and distribution. China also received regulatory support for longer-acting ESA regimens when the NMPA approved 3SBio’s extended-half-life erythropoietin (SSS06) in March 2026 for anemia in CKD patients on hemodialysis, aligning with provider interest in reducing dosing frequency. In rarer indications, development programs are advancing through pivotal-stage studies, including Takeda’s Phase 3 trial (NCT07422480) initiated in May 2026 in myelodysplastic syndromes, reinforcing pipeline-led opportunity in transfusion-dependent anemia where options remain constrained by safety, cost containment, and logistics.